Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

Technology Scientific & Technical Instruments
RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Replicel Life Sciences Inc > CONTACT CIRO FOR LIFTING TRADING BAN !!
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(12)
•••
Post by MetzGERon Jun 30, 2024 2:09am
244 Views
Post# 36112475

CONTACT CIRO FOR LIFTING TRADING BAN !!

CONTACT CIRO FOR LIFTING TRADING BAN !!Please all contact CIRO (Canadian Investment Regulatory organization)

Report to the CIRO that the trading halt of Replicel Must be canceled immediately. After RepliCels hair regeneration technology was commercialized of Shiseido Company Replicel is a very valuable Company Holding worldwide rights of this Technology in Europe, America, South America... 
Replicel has to be back on the Stock msrket
immediately

https://www.ciro.ca/contact-us

Complaints & Inquiries

Investors (clients or prospective clients of investment firms) and members of the public should direct all questions or complaintsto our dedicated Complaints and Inquiries team (in English or French). Contacting other CIRO departments directly could result in delays.

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities